Most Alzheimer's research centres on two proteins, amyloid beta and tau. A team at Neuro-Bio in Abingdon and the University of Nottingham suggests that a small peptide called T30 may sit further upstream. In rats, infusing it into a small area deep in the brain was followed by higher levels of both proteins. The study, led by Watkinson and colleagues, was published in Neurochemical Research on 31 October 2026.
This is animal work. The rats showed changes in brain tissue, but not in the behavioural tests the team ran.
What T30 is
T30 is a peptide taken from acetylcholinesterase, an enzyme best known for breaking down the messenger chemical acetylcholine. The active part of T30 is a 14 amino acid stretch called T14.
Earlier work from the same research programme has linked these peptides to a mechanism that may act before amyloid builds up, which is why the group studies them as a possible driver of the disease rather than a by-product.
What the team did
The researchers infused T30 into a small area deep in the rat brain, twice a week for three weeks.
Afterwards the rats had more amyloid beta and more phosphorylated tau in the cortex, the hippocampus and the midbrain. There were also signs of nerve cell loss.
No change in memory or movement
Despite these changes in the tissue, the rats' memory and movement tests did not change over the period studied. The report does not claim that T30 produced a full model of the disease in behaviour.
The team also found that levels of T14 followed levels of its parent enzyme, but not the enzyme's usual activity. The authors read this as a sign that the peptide may work independently of the enzyme's familiar role.
Why it matters, and the limits
The authors see the approach as a possible new route for modelling the disease in animals, one that starts from a brain peptide rather than from amyloid or tau directly.
It remains a single rat study. Whether the same chain of events happens in people, and whether blocking T30 or T14 would change anything, are questions for later work.